Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SURE-01: Neoadjuvant Sacituzumab Govitecan in Muscle-invasive Bladder Cancer
NCT05226117Phase 2Completed
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Mar 2022
- Primary completion
- Sep 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab govitecan in urothelial carcinoma (UC), sponsored by IRCCS Ospedale San Raffaele. Started Mar 2022; status: completed.
02
Drugs
sacituzumab govitecan
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT05226117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05226117.